Tachykinin NK2 receptor antagonists. A patent review (2006 – 2010)

Bibliography

• Maggi CA, Patacchini R, Rovero P, Giachetti A. Tachykinin receptors and tachykinin receptor antagonists. J Auton Pharmacol 1993;13:23-93
   PubMedGoogle Scholar
• Pennefather JN, Lecci A, Luz Candenas M, Tachykinin and tachykinin receptors: a growing family. Life Sci 2004;74:1445-63
   PubMed Web of Science ®Google Scholar
• Evangelista S, Patacchini R, Maggi CA. Role of peripheral tachykinin receptors in neurogenic inflammation of the respiratory, genitourinary and gastrointestinal systems. Curr Med Chem Anti Inflamm Anti Allergy Agents 2003;2:157-74
   Google Scholar
• Quartara L, Altamura M, Evangelista S, Maggi CA. Tachykinin receptor antagonists in clinical trials. Expert Opin Invest Drugs 2009;18:1843-64
   PubMed Web of Science ®Google Scholar
• Bensaid M, Faucheux BA, Hirsch E, Expression of tachykinin NK2 receptor mRNA in human brain. Neurosci Lett 2001;303:25-8
   PubMed Web of Science ®Google Scholar
• Saffroy M, Torrens Y, Glowinski J, Autoradiographic distribution of tachykinin NK2 binding sites in the rat brain: comparison with NK1 and NK3 binding sites. Neuroscience 2003;116:761-73
   PubMed Web of Science ®Google Scholar
• Nagano M, Oishi T, Suzuki H. Distribution and pharmacological characterization of primate NK2 tachykinin receptor in the central nervous system of the rhesus monkey. Neurosci Lett 2011;503:23-6
   PubMed Web of Science ®Google Scholar
• Albert JS. Neurokinin antagonists and their potential role in treating depression and other stress disorders. Expert Opin Ther Patents 2004;14:1421-33
   Web of Science ®Google Scholar
• Steinberg R, Alonso R, Griebel G, Selective blockade of neurokinin-2 receptors produces antidepressant-like effects associated with reduced corticotropin-releasing factor function. J Pharmacol Exp Ther 2001;299:449-58
   PubMed Web of Science ®Google Scholar
• Louis C, Stemmelin J, Boulay D, Additional evidence for anxiolytic- and antidepressant-like activities of saredutant (SR48968), an antagonist at the neurokinin-2 receptor in various rodent-models. Pharmacol Biochem Behav 2008;89:36-45
   PubMed Web of Science ®Google Scholar
• Le Fur G. Sanofi-aventis Information Meeting; February 16 2004
   Google Scholar
• Phase III clinical trials reported in the ClinicalTrials.gov database. Available from: http://www.clinicaltrials.gov [Last accessed 15 September 2011]
   Google Scholar
• Sanofi-aventis Press Release, July 31, 2008
   Google Scholar
• Sanofi-aventis Press Release, April 29, 2009
   Google Scholar
• Shimizu Y, Matsuyama H, Shiina T, Tachykinin and their functions in the gastrointestinal tract. Cell Mol Life Sci 2008;65:295-311
   PubMed Web of Science ®Google Scholar
• Jaafari N, Khomitch-Baud A, Christen MO, Distribution pattern of tachykinin NK2 receptors in human colon: involvement in the regulation of intestinal motility. J Comp Neurol 2007;503:381-91
   PubMed Web of Science ®Google Scholar
• Maggi CA, Patacchini R, Santicioli P, Human isolated ileum: motor responses of the circular muscle to electrical field stimulation and exogenous neuropeptides. Naunyn Schmiedebergs Arch Pharmacol 1990;341:256-61
   PubMed Web of Science ®Google Scholar
• Giuliani S, Barbanti G, Turini D, NK2 tachykinin receptors and contraction of circular muscle of the human colon: characterization of the NK2 receptor subtype. Eur J Pharmacol 1991;203:365-70
   PubMed Web of Science ®Google Scholar
• Giuliani S, Guelfi M, Toulouse M, Effect of a tachykinin NK2 receptor antagonist, nepadutant, on cardiovascular and gastrointestinal function in rats and dogs. Eur J Pharmacol 2001;415:61-71
   PubMed Web of Science ®Google Scholar
• Lecci A, Capriati A, Maggi CA. Tachykinin NK2 receptor antagonists for the treatment of irritable bowel syndrome. Br J Pharmacol 2004;141:1249-63
   PubMed Web of Science ®Google Scholar
• Toulouse M, Coelho AM, Fioramonti J. Role of tachykinin NK2 receptors in normal and altered rectal sensitivity in rats. Br J Pharmacol 2000;129:193-9
   PubMed Web of Science ®Google Scholar
• Lecci A, Capriati A, Altamura M, Maggi CA. Tachykinin and tachykinin receptors in the gut, with special reference to NK2 receptors in human. Auton Neurosci 2006;126-7:232-49
   Web of Science ®Google Scholar
• Lordal M, Navalesi G, Theodorsson E, A novel tachykinin NK2 receptor antagonist prevents motility-stimulating effects of neurokinin A in small intestine. Br J Pharmacol 2001;134:215-23
   PubMed Web of Science ®Google Scholar
• Menarini Group. Study NCT00761007. Double-blind, randomised, placebo-controlled, parallel group study to evaluate the effect of a 4-week treatment with oral doses of ibodutant (code: MEN15596) in Irritable Bowel Syndrome (IBS). Available from: http://www.clinicaltrials.gov [Last accessed 16 September 2011]
   Google Scholar
• Menarini Group. Study NCT01303224. Double-blind, randomised, placebo-controlled, parallel-group Phase II study to evaluate the effect of oral ibodutant in Irritable Bowel Syndrome with Diarrhoea (IBS-D). Available from: http://www.clinicaltrials.gov [Last accessed 16 September 2011]
   Google Scholar
• Zakko S, Barton G, Weber E, Randomised clinical trial: the clinical effects of a novel neurokinin receptor antagonist, DNK333, in women with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2011;33:1311-21
   PubMed Web of Science ®Google Scholar
• Rogers DF. Tachykinin receptor antagonists for asthma and COPD. Expert Opin Ther Patents 2001;11:1097-121
   Web of Science ®Google Scholar
• Altamura M, Manzini S, Lecci A. Tachykinin receptors in chronic inflammatory lower airway diseases. Expert Opin Ther Patents 2007;17:1241-73
   Web of Science ®Google Scholar
• Ramalho R, Soares R, Couto N, Moreira A. Tachykinin receptors antagonism for asthma: a systematic review. BMC Pulm Med 2011;11:41
   PubMed Web of Science ®Google Scholar
• Kraan J, Vink-Klooster H, Postma DS. The NK-2 receptor antagonist SR 48968C does not improve adenosine hyperresponsiveness and airway obstruction in allergic asthma. Clin Exp Allergy 2001;31:274-8
   PubMed Web of Science ®Google Scholar
• Boot JD, de Haas S, Tarasevych S, Effect of an NK1/NK2 receptor antagonist on airway responses and inflammation to allergen in asthma. Am J Respir Crit Care Med 2007;175:450-7
   PubMed Web of Science ®Google Scholar
• Candenas L, Lecci A, Pinto FM, Tachykinins and tachykinin receptors: effects in the genitourinary tract. Life Sci 2005;7:835-62
   Google Scholar
• Malherbe P, Ballard TM, Ratni H. Tachykinin neurokinin 3 receptor antagonists: a patent review (2005 - 2010). Expert Opin Ther Patents 2011;21:637-55
   PubMed Web of Science ®Google Scholar
• Huang SC, Korlipara VL. Neurokinin-1 receptor antagonists: a comprehensive patent survey. Expert Opin Ther Patents 2010;20:1019-45
   PubMed Web of Science ®Google Scholar
• AstraZeneca AB. Novel treatment of gastrointestinal disorders. WO06062478;2006
   Google Scholar
• AstraZeneca AB. New azetidine compounds. WO04110344;2004
   Google Scholar
• AstraZeneca AB. Novel crystalline form of 3,5-dibromo-N-[(2S)-2-(-4-fluorophenyl)-4-(3-morpholin-4-ylazetidin-1-yl)butyl]-N-methylbenzamide, modification A. WO07043939;2007
   Google Scholar
• AstraZeneca AB. Novel crystalline form of 3,5-dibromo-N-[(2S)-2-(-4-fluorophenyl)-4-(3-morpholin-4-ylazetidin-1-yl)butyl]-N-methylbenzamide, modification B. WO07043938;2007
   Google Scholar
• AstraZeneca AB. Use of a neurokinin-2 receptor antagonist for treating or preventing detrusor overactivity. WO06121389;2006
   Google Scholar
• AstraZeneca AB. Compounds and method for the treatment of overactive bladder. WO03037889;2003
   Google Scholar
• Abdel-Karim AM, Barthlow HG, Bialecki RA, Elhilali MM. Effects of M274773, a neurokinin-2 receptor antagonist, on bladder function in chronically spinalized rats. J Urol 2005;174:1488-92
   PubMed Web of Science ®Google Scholar
• AstraZeneca AB. New azetidine derivatives as neurokinin receptor antagonists for the treatment of gastrointestinal diseases. WO06137790;2006
   Google Scholar
• AstraZeneca AB. New azetidine derivatives as neurokinin receptor antagonists for the treatment of gastrointestinal diseases. WO06137791;2006
   Google Scholar
• AstraZeneca AB. Novel azetidine compounds useful in the treatment of functional gastrointestinal disorders, IBS and functional dyspepsia. WO07037742;2007
   Google Scholar
• AstraZeneca AB. Novel azetidine compounds useful in the treatment of functional gastrointestinal disorders, IBS and functional dyspepsia. WO07037743;2007
   Google Scholar
• AstraZeneca AB. 1-[(4-[benzoyl(methyl) amino]-3-(phenyl)butyl]azetidine derivatives for the treatment of gastrointestinal disorders 1. WO07136324;2007
   Google Scholar
• AstraZeneca AB. 1-[(4-[benzoyl(methyl) amino]-3-(phenyl)butyl]azetidine derivatives for the treatment of gastrointestinal disorders 2. WO07136325;2007
   Google Scholar
• AstraZeneca AB. New compounds 302. WO07136326;2007
   Google Scholar
• AstraZeneca AB. Azetidin-azabicyclo[3.2.1]octan derivatives that are neurokinin (NK) receptor antagonists and their use. WO08076041;2008
   Google Scholar
• AstraZeneca AB. Azetidinpiperazine derivatives that are neurokinin (NK) receptor antagonists and their use. WO08076042;2008
   Google Scholar
• Albireo AB. A fumarate salt of 3-bromo-N-{(2S)-2-(4-fluorophenyl)-4-[3-(4-acetylpiperazin-l-yl)azetidin-1-yl]butyl}-N-methyl-5-(trifluoromethyl)benzamide for the treatment of gastrointestinal disorders. WO08118091;2008
   Google Scholar
• Albireo AB. Maleate salt of 3-bromo-N-{(2S)-2-(4-fluorophenyl)-4-[3-(4-acetylpiperazin-1-yl)azetidin-1-yl]butyl}-N-methyl-5-(trifluoromethyl)benzamide for the treatment of gastrointestinal disorders. WO08118092;2008
   Google Scholar
• Albireo Pharma, Co. website. Available from: http://www.albireopharma.com [Last accessed 6 October 2011]
   Google Scholar
• Merck Sharp & Dohme Ltd. Quinoline derivatives as neurokinin receptor antagonists. WO06013393;2006
   Google Scholar
• Merck Sharp & Dohme Ltd. Quinoline derivatives as neurokinin receptor antagonists. WO06013394;2006
   Google Scholar
• Quartara L, Altamura M. Tachykinin receptors antagonists: from research to clinic. Curr Drug Targets 2006;7:975-92
   PubMed Web of Science ®Google Scholar
• Merck Sharp & Dohme Ltd. Quinoline derivatives as neurokinin receptor antagonists. WO06120478;2006
   Google Scholar
• Merck Sharp & Dohme Ltd. Quinoline derivatives as neurokinin receptor antagonists. WO07012900;2007
   Google Scholar
• Sanofi-Aventis. 4-arylmorpholin-3-one derivatives, preparation and therapeutic use thereof. WO06021654;2006
   Google Scholar
• Emonds-Alt X, Advenier C, Cognon C, Biochemical and pharmacological activities of SR 144190, a new potent non-peptide tachykinin NK2 receptor antagonist. Neuropeptides 1997;31:449-58
   PubMed Web of Science ®Google Scholar
• Takeda Pharmaceutical Co. Ltd. Pyrroloquinoline derivative and use thereof. WO08153027;2008
   Google Scholar
• Takeda Pharmaceutical Co. Ltd. Fused quinoline derivative and use thereof. WO05105802;2005
   Google Scholar
• Takeda Pharmaceutical Co. Ltd. Dihydropyrroloquinoline derivatives. WO11055810;2011
   Google Scholar
• Takeda Pharmaceutical Co. Ltd. Nitrogen-containing heterocyclic compound and use thereof. WO09072643;2009
   Google Scholar
• Takeda Pharmaceutical Co. Ltd. Nitrogen-containing heterocyclic compound and use of same. WO10032856;2010
   Google Scholar
• Takeda Pharmaceutical Co. Ltd. Quinolone derivative and use thereof. WO09128262;2009
   Google Scholar
• F. Hoffmann-La Roche AG. Spiropiperidine derivatives as NK3 antagonists. WO08081012;2008
   Google Scholar
• F. Hoffmann-La Roche AG. Pyrrolidine derivatives as NK2 receptor antagonists. WO09153179;2009
   Google Scholar
• Solvay Pharmaceuticals GmbH. Novel NK1 and NK2 antagonists. WO07063086;2007
   Google Scholar
• Solvay Pharmaceuticals GmbH. Novel dual NK2/NK3-antagonists, pharmaceutical compositions comprising them and processes for their preparations. WO07088181;2007
   Google Scholar
• Zentaris GmbH, Solvay Pharmaceutical BV. Novel tetrahydrocarbazole derivatives with improved biological action and improved solubility as ligands for G-protein coupled receptors (GPCRs). WO06005484;2006
   Google Scholar
• Aeterna Zentaris GmbH. Novel tetrahydrocarbazole derivatives as ligands of G-protein coupled receptors. WO08132153;2008
   Google Scholar
• Daiichi Sankyo Co. Ltd. Amide derivative. WO10106988;2010
   Google Scholar
• Tsuchida H, Takahashi S, Nosaka E, Novel triple neurokinin receptor antagonist CS-003 inhibits respiratory disease models in guinea pigs. Eur J Pharmacol 2008;596:153-9
   PubMed Web of Science ®Google Scholar
• United Paragon Associates, Inc. Fertilized egg isolate and use thereof. WO09086634;2009
   Google Scholar
• Mount Sinai Hospital, Canada. Study NCT00446719. Safety and Antidepressant Effects of Rellidep in Major Depressive Disorder. Available from: http://www.clinicaltrials.gov [Last accessed 6 September 2011]
   Google Scholar
• United Paragon Associates, Inc. Compounds for treating disorders or diseases associated with neurokinin 2 receptor activity. WO11029099;2011
   Google Scholar
• Sanofi-Synthelabo. Novel piperidinecarboxamide derivatives, method for preparing same and pharmaceutical compositions containing same. WO02094821; 2002
   Google Scholar
• Sanofi-Aventis. Use of a compound antagonist to the NK2 receptors of a neurokinine for the preparation of drugs useful for preventing and treating sexual dysfunction. WO08110697;2008
   Google Scholar
• Sanofi-Aventis. Pharmaceutical composition containing saredutant and a selective inhibitor of serotonin recapture or an inhibitor of serotonin/norepinephrine recapture in combination. WO08017753; 2008
   Google Scholar
• Louis C, Cohen C, Depoortere R, Griebel G. Antidepressant-like effects of the corticotropin-releasing factor 1 receptor antagonist, SSR125543, and the vasopressin 1b receptor antagonist, SSR149415, in a DRL-72 s schedule in the rat. Neuropsychopharmacology 2006;31:2180-7
   PubMed Web of Science ®Google Scholar
• Sanofi-Aventis. Study NCT00629551. An Eight-Week Study of Saredutant and Paroxetine as Combination Treatment for Major Depressive Disorder (COMPASS). Available from: http://www.clinicaltrials.gov [Last accessed 24 August 2011]
   Google Scholar
• Sanofi-Aventis. Study NCT00531622. An Eight-Week Study of Saredutant and Escitalopram as Combination Treatment for Major Depressive Disorder. Available from: http://www.clinicaltrials.gov [Last accessed 24 August 2011]
   Google Scholar
• Laboratori Guidotti (Menarini Group). Pharmaceutical compositions based on NK2 antagonists for pediatric use. WO06045820;2006
   Google Scholar
• Menarini Group. Study NCT01258153. Preliminary Efficacy and Safety Study of Oral Nepadutant in Infant Colic (No-Cry). Available from: http://www.clinicaltrials.gov [Last accessed 24 August 2011]
   Google Scholar
• Menarini Group. Study NCT01309009. Preliminary Efficacy and Safety Study of Oral Nepadutant in Infant With Colic Not Responding to Conventional Treatment (NoCry-a). Available from: http://www.clinicaltrials.gov [Last accessed 24 August 2011]
   Google Scholar
• Tramontana M, Evangelista S, Giuliani S, Influence of tachykinin NK2 receptors on intestinal sensitivity and motility in newborn rats. Neuropeptides 2010;44:269-72
   PubMed Web of Science ®Google Scholar
• Novartis AG. Uses of NK receptor antagonists. WO10097381;2010
   Google Scholar
• Novartis Pharmaceuticals. Study NCT01033097. A multicenter, randomized, double-blinded, placebo and positive controlled study to evaluate the anti-pruritic effect, safety and tolerability, systemic and skin exposure, after 2 weeks of treatment with a microemulsion formulation of DNK333 in atopic dermatitis patients. Available from: http://www.clinicaltrials.gov [Last accessed 28 September 2011]
   Google Scholar
• Sosei Co. Ltd. Azapeptides for use in therapy. WO08012546; 2008
   Google Scholar
• Sosei Co. Ltd. & Neurosolutions Ltd. Azapeptides for treating hyperalgesic pain conditions. WO07020403;2007
   Google Scholar
• Higashide Y, Yatabe Y, Arai Y, Pharmacological profiles of a novel tachykinin NK2 receptor antagonist, TAC-363. Yakugaku Zasshi 1996;116:884-91
   PubMed Web of Science ®Google Scholar
• Higashide Y, Yatabe Y, Arai Y, Effect of a novel tachykinin NK2 receptor antagonist, TAC-363, on bronchoconstriction and airway hyperresponsiveness in guinea pigs. Folia Pharmacol Jpn 1997;109:19-29
   PubMedGoogle Scholar
• Adelaide Research & Innovation Pty Ltd. & James Cook University. Method for reducing inflammatory responses and inflammation. WO08067609;2008
   Google Scholar
• Adelaide Research & Innovation Pty Ltd & James Cook University. Method for reducing inflammatory responses and inflammation. WO08067610;2008
   Google Scholar
• Adelaide Research & Innovation Pty Ltd. Use of substance P receptor antagonists - for the treatment of intracranial pressure. WO09009829;2009
   Google Scholar
• Adelaide Research & Innovation Pty Ltd. Method for preventing and/or treating a disease, condition or state associated with reduced dopaminergic neuron function. WO09109001;2009
   Google Scholar
• Amatya B, El-Nour H, Holst M, Expression of tachykinins and their receptors in plaque psoriasis with pruritus. Br J Dermatol 2011;164:1023-9
   PubMed Web of Science ®Google Scholar